pharmaphorum

OCTOBER 1, 2021

Shares in DNA sequencing specialist Oxford Nanopore rocketed after the company made its debut on the London Stock Exchange yesterday, rising nearly 50% to propel its valuation up towards the £5 billion ($6.7 It may also use the cash injection for “in-licensing opportunities and potential acquisitions”, according to the document.

Marketing 52

Marketing Business Development Genome Genomics 52

The Pharma Data

JUNE 7, 2023

In addition to mRNA, Acuitas LNP can be used to deliver a range of different nucleic acid therapeutics including small interfering RNA (siRNA), antisense oligonucleotides and DNA. “Accessing state-of-the-art LNP technology through this collaboration will add momentum to our gene editing efforts for the benefit of patients.”

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

The Pharma Data

OCTOBER 26, 2020

billion related to certain license and collaboration agreements, and certain other items. 50%) with no EGFR or ALK genomic tumor aberrations. L1 expression with no EGFR or ALK genomic tumor aberrations at the IASLC 2020 North America Conference on Lung Cancer (NACLC). Business Developments.

Sales 40

Sales Vaccination Vaccine Production 40

Drug Discovery World

SEPTEMBER 6, 2022

Fully booked service providers for manufacturing and sample analyses and more immune-oriented use of gene and cell therapies.” – CBO Aino Kalervo, and VP of Business Development? Research into genomic medicines is only at its infancy. .” – Andrew Scharenberg, Umoja Biopharma CEO. . Workforce .

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52